Opioid agonist/antagonist combinations

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7749542
APP PUB NO 20080292694A1
SERIAL NO

12220760

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT464

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, US 21 1958
Kaiko, Robert F Weston, US 47 3188

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (5)
5376662 Method of attenuating nerve injury induced pain 77 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 57 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 82 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 74 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 45 2003
 
NOVA PHARMACEUTICAL CORPORATION (2)
4760069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 90 1985
4889860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 98 1987
 
The Lynx Project Limited (1)
6310072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 78 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5352683 Method for the treatment of chronic pain 130 1993
5321012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 214 1993
5502058 Method for the treatment of pain 192 1994
5556838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 190 1994
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (1)
5225440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 83 1991
 
ELI LILLY AND COMPANY (1)
5998434 Composition for treating pain 69 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4803208 Opiate agonists and antagonists 78 1985
 
ICN HUNGARY RT. (1)
5317022 Pharmaceutical composition and use 81 1992
 
G. D. Searle & Co. (1)
5616601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 180 1995
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5426112 Growth regulation and related applications of opioid antagonists 146 1993
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4873076 Method of safely providing anesthesia or conscious sedation 92 1989
 
OMEROS CORPORATION (2)
5858017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 138 1996
5860950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 126 1996
 
COLMAN PRODUCTS LIMITED (1)
4935428 Treating opiate dependence 106 1988
 
The Rockefeller University (3)
4987136 Method for controlling gastrointestinal dysmotility 156 1986
4769372 Method of treating patients suffering from chronic pain or chronic cough 189 1986
4785000 Method of treating patients suffering from chronic pain or chronic cough 133 1987
 
ADIR ET COMPAGNIE (1)
5130311 Oxazolopyridine compounds, compositions and use 108 1991
 
Schaap; Robert J. (2)
5316759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 105 1992
5574052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 167 1994
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4451470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 92 1982
5593994 Prostaglandin synthase inhibitors 127 1994
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4457933 Prevention of analgesic abuse 207 1981
 
DynaGen, Inc. (1)
5486362 Controlled, sustained release delivery system for treating drug dependency 143 1993
 
MERCK SHARP & DOHME LTD. (1)
5880132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 82 1997
 
Warner-Lambert Company (1)
5149538 Misuse-resistive transdermal opioid dosage form 267 1991
 
THE UNIVERSITY OF CHICAGO (4)
4719215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 124 1986
4861781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 118 1987
5102887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 117 1990
5972954 Use of methylnaltrexone and related compounds 135 1997
 
UNITED BIOMEDICAL, INC. (2)
5633259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 77 1995
5624932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 76 1995
 
UNIVERSITY OF OREGON (1)
5514680 Glycine receptor antagonists and the use thereof 127 1993
 
MERCK FROSST COMPANY (1)
5474995 Phenyl heterocycles as cox-2 inhibitors 223 1994
 
CONTRAL CLINICS OY (3)
4882335 Method for treating alcohol-drinking response 103 1988
5096715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 86 1989
5086058 Method for treating alcoholism with nalmefene 99 1990
 
ALZA CORPORATION (4)
4573995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 183 1984
5236714 Abusable substance dosage form having reduced abuse potential 150 1988
5460826 Morphine therapy 170 1994
5866164 Composition and dosage form comprising opioid antagonist 281 1997
 
YOUNG, JACQUELINE, MS. (1)
5356900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 80 1993
 
SIMON, DAVID L. (1)
6103258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 72 1998
 
MERCK FROSST CANADA LTD. (10)
5409944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 132 1993
5604260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 151 1993
5436265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 151 1993
5521213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 158 1994
5552422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 171 1995
5536752 Phenyl heterocycles as COX-2 inhibitors 148 1995
5550142 Phenyl heterocycles as cox-2 inhibitors 152 1995
5510368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 150 1995
5604253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 139 1995
5639780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 136 1995
 
EURO-CELTIQUE S.A. (35)
4366310 Controlled release compositions 115 1980
4443428 Extended action controlled release compositions 181 1982
4940587 Oral pharmaceutical composition through mucosa 135 1986
4844907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 161 1986
4834965 Controlled release pharmaceutical composition 119 1987
4867985 Spheroids 113 1988
5071646 Pharmaceutical ion exchange resin composition 164 1989
5091189 Controlled release dosage forms having a defined water content 64 1991
5215758 Controlled release matrix suppository for pharmaceuticals 152 1991
5324351 Aqueous dispersions of zein and preparation thereof 184 1992
5356467 Controlled release coatings derived from aqueous dispersions of zein 286 1993
5500227 Immediate release tablet cores of insoluble drugs having sustained-release coating 251 1993
5622722 Spheroid formulation 66 1994
5508043 Controlled release matrix for pharmaceuticals 99 1995
5670172 Pharmaceutical spheroid formulation 115 1995
6024982 Immediate release tablet cores of insoluble drugs having sustained-release coating 175 1995
5811126 Controlled release matrix for pharmaceuticals 172 1995
5763452 Pharmaceutical compositions and usages 62 1996
5849240 Method of preparing sustained release pharmaceutical compositions 243 1996
5891471 Pharmaceutical multiparticulates 200 1996
5601845 Pharmaceutical spheroid formulation 114 1996
5843480 Controlled release diamorphine formulation 164 1996
5879705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 206 1997
5908848 Synergistic composition of codine and ibuprofen to treat arthritis 64 1997
5942241 Formulations and methods for providing prolonged local anesthesia 188 1997
6068855 Pharmaceutical composition containing a fusible carrier and method for producing the same 105 1997
5965163 Substained release compositions and a method of preparing pharmaceutical compositions 211 1997
6077532 Pharmaceutical ion exchange resin composition 71 1998
6306438 Stabilized sustained release tramadol formulations 120 1998
6399096 Pharmaceutical formulation 121 1998
6143328 Sustained release compositions and a method of preparing pharmaceutical compositions 87 1999
6162467 Sustained release compositions and a method of preparing pharmaceutical compositions 174 1999
6210714 Immediate release tablet cores of acetaminophen having sustained-release coating 133 2000
6387404 Immediate release tablet cores of insoluble drugs having sustained-release coating 134 2001
6627635 Method of preventing abuse of opioid dosage forms 182 2001
 
PURDUE PHARMA L.P. (40)
4828836 Controlled release pharmaceutical composition 243 1987
4834985 Controlled release pharmaceutical composition 249 1987
4990341 Controlled release hydromorphone composition 229 1989
5266331 Controlled release oxycodone compositions 326 1991
5273760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 327 1991
5286493 Stabilized controlled release formulations having acrylic polymer coating 323 1992
5549912 Controlled release oxycodone compositions 317 1993
5472712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 315 1993
5478577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 333 1993
5411745 Powder-layered morphine sulfate formulations 209 1994
5965161 Extruded multi-particulates 265 1994
5639476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 639 1995
5508042 Controlled release oxycodone compositions 356 1995
5968551 Orally administrable opioid formulations having extended duration of effect 339 1995
5958459 Opioid formulations having extended controlled released 225 1995
5656295 Controlled release oxycodone compositions 303 1996
5681585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 190 1996
5672360 Method of treating pain by administering 24 hour oral opioid formulations 305 1996
6143322 Method of treating humans with opioid formulations having extended controlled release 228 1997
5958452 Extruded orally administrable opioid formulations 309 1997
5968547 Method of providing sustained analgesia with buprenorphine 128 1997
6077533 Powder-layered oral dosage forms 96 1998
6228863 Method of preventing abuse of opioid dosage forms 286 1998
* 6277384 Opioid agonist/antagonist combinations 179 1998
6103261 Opioid formulations having extended controlled release 211 1999
6335033 Melt-extrusion multiparticulates 159 1999
6261599 Melt-extruded orally administrable opioid formulations 234 1999
6294195 Orally administrable opioid formulations having extended duration of effect 191 1999
6375957 Opioid agonist/opioid antagonist/acetaminophen combinations 297 2000
6696088 Tamper-resistant oral opioid agonist formulations 240 2001
6716449 Controlled-release compositions containing opioid agonist and antagonist 134 2001
* 6475494 Opioid agonist/antagonist combinations 151 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 95 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 89 2002
* 6696066 Opioid agonist/antagonist combinations 209 2002
2003/0229,111 Naltrexone hydrochloride compositions 44 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 67 2003
* 7172767 Opioid agonist / antagonist combinations 122 2003
2006/0182,801 Sequestered antagonist formulations 84 2006
* 7419686 Opioid agonist/antagonist combinations 76 2006
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4844909 Controlled release hydromorphone composition 223 1987
4844910 Spheroids 74 1987
 
McGinnis; Carolyn (1)
4608376 Opiate agonists and antagonists 74 1982
 
AMINOTEK SCIENCES, INC. A CORP. OF NEW JERSEY (1)
5256669 Methods and compositions for treating acute or chronic pain and drug addiction 82 1992
 
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (1)
4464378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 236 1981
 
PEPTECH (UK) LIMITED (1)
5534492 Muramyl peptide for the treatment of toxicity 71 1995
 
The United States of America as represented by the Secretary of the Army (1)
5834477 Opiate analgesic formulation with improved safety 67 1994
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (5)
5472943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 179 1993
5585348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 105 1993
* 5580876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 120 1995
6194382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 81 1999
6765010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 68 2002
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4582835 Analgesic compositions 165 1984
4661492 Analgesic compositions 133 1985
 
GENERAL ELECTRIC COMPANY (1)
5226331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 49 1991
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4806341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 209 1986
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (6)
* 5512578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 134 1994
5767125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 120 1996
6096756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 153 1998
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 56 1999
6362194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 70 2000
6395705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 77 2001
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4806543 Method and compositions for reducing neurotoxic injury 101 1986
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4401672 Non-addictive narcotic antitussive preparation 86 1981
4730048 Gut-selective opiates 119 1985
5352680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 135 1992
5457208 Kappa opioid receptor antagonists 97 1993
5578725 Delta opioid receptor antagonists 80 1995
5780479 Use of opioid antagonists to treat impulse-control disorders 75 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5075341 Treatment for cocaine abuse 171 1989
 
Ortho-McNeil Pharmaceutical, Inc. (1)
5336691 Composition comprising a tramadol material and acetaminophen and its use 109 1992
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5591452 Controlled release formulation 124 1994
6326027 Controlled release formulation 118 1995
6254887 Controlled release tramadol 128 1996
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5869097 Method of therapy comprising an osmotic caplet 101 1992
 
PURDUE PHARMA COMPANY, THE (2)
4861598 Controlled release bases for pharmaceuticals 300 1986
4970075 Controlled release bases for pharmaceuticals 257 1989
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4722928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 44 1985
 
PUREUE PHARMA L.P. (1)
4834984 Controlled release dihydrocodeine composition 211 1987
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 24 2003
 
BASF AKTIENGESELLSCHAFT (2)
4806558 Diarylacetylenes and their use in treating acne 76 1985
4957681 Preparation of pharmaceutical mixtures 185 1989
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
RECRO GAINESVILLE LLC (4)
9132096 Abuse resistant pharmaceutical compositions 2 2014
9486451 Abuse resistant pharmaceutical compositions 0 2015
9452163 Abuse resistant pharmaceutical compositions 0 2015
9713611 Abuse resistant pharmaceutical compositions 0 2016
 
Other [Check patent profile for assignment information] (1)
9943513 Opioid abuse deterrent dosage forms 0 2016
 
BANNER LIFE SCIENCES LLC (1)
9861629 Opioid abuse deterrent dosage forms 0 2016
 
EURO-CELTIQUE S.A. (2)
9901540 Combination of active loaded granules with additional actives 0 2011
9814710 Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome 0 2014
 
PURDUE PHARMA L.P. (30)
8518925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 6 2005
9101625 Buprenorphine-wafer for drug substitution therapy 1 2007
8987290 Use of opioid formulations in needle-less drug delivery devices 1 2007
* 2010/0056,554 USE OF OPIOID FORMULATIONS IN NEEDLE-LESS DRUG DELIVERY DEVICES 0 2007
9271940 Immediate release pharmaceutical compositions comprising oxycodone and naloxone 0 2010
* 8105631 Opioid agonist/antagonist combinations 50 2010
8673355 Opioid agonist/antagonist combinations 23 2011
8846090 Matrix for sustained, invariant and independent release of active compounds 25 2012
8822487 Opioid agonist/opioid antagonist/acetaminophen combinations 23 2012
8846091 Matrix for sustained, invariant and independent release of active compounds 24 2013
9084729 Abuse-resistant controlled-release opioid dosage form 6 2013
8969369 Abuse-resistant controlled-release opioid dosage form 24 2013
9056051 Abuse-resistant controlled-release opioid dosage form 8 2014
9205082 Opioid agonist/antagonist combinations 4 2014
9555000 Pharmaceutical preparation containing oxycodone and naloxone 2 2014
9474750 Opioid agonist/opioid antagonist/acetaminophen combinations 2 2014
9655855 Matrix for sustained, invariant and independent release of active compounds 2 2014
8936808 Opioid agonist/opioid antagonist/acetaminophen combinations 8 2014
8932630 Opioid agonist/antagonist combinations 8 2014
9168252 Abuse-resistant controlled-release opioid dosage form 4 2015
9161937 Abuse-resistant controlled-release opioid dosage form 6 2015
9283216 Abuse-resistant controlled-release opioid dosage form 2 2015
9283221 Abuse-resistant controlled-release opioid dosage form 2 2015
9820983 Immediate release pharmaceutical compositions comprising oxycodone and naloxone 0 2016
9358230 Abuse-resistant controlled-release opioid dosage form 2 2016
9345701 Abuse-resistant controlled-release opioid dosage form 2 2016
9763931 Buprenorphine-wafer for drug substitution therapy 0 2016
9511066 Abuse-resistant controlled-release opioid dosage form 2 2016
9480685 Abuse-resistant controlled-release opioid dosage form 2 2016
9907793 Pharmaceutical preparation containing oxycodone and naloxone 0 2017
 
QRxPHARMA Ltd. (1)
* 8933092 Methods and compositions comprising sequential administration opioid receptor agonists 1 2012
 
RHODES PHARMACEUTICALS L.P. (2)
9370512 Buprenorphine-wafer for drug substitution therapy 1 2015
9861628 Buprenorphine-wafer for drug substitution therapy 0 2016
 
EGALET LTD. (11)
8877241 Morphine controlled release system 5 2004
9005660 Immediate release composition resistant to abuse by intake of alcohol 7 2010
9023394 Formulations and methods for the controlled release of active drug substances 5 2013
9694080 Polymer release system 0 2013
8808745 Morphine polymer release system 9 2013
9044402 Abuse-deterrent pharmaceutical compositions for controlled release 7 2014
9707179 Opioid polymer release system 0 2014
9642809 Controlled release pharmaceutical compositions for prolonged effect 0 2014
9375428 Morphine controlled release system 2 2014
9358295 Immediate release composition resistant to abuse by intake of alcohol 4 2015
9884029 Morphine controlled release system 0 2016
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00